Single-dose, patient-controlled injector approved for plaque psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya (guselkumab) is the first FDA-approved medication of its kind to offer the One-Press patient-controlled injector. One-Press was designed with patients in mind: it fits comfortably in the hand and offers a controlled injection that hides the needle throughout the process. Tremfya is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. Tremfya is intended for use under the guidance and supervision of a physician, and patients may self-inject with Tremfya One-Press after physician approval and proper training. Tremfya One-Press is now available in the U.S.

In the Phase III, multicenter and randomized ORION study, patient experience with One-Press was assessed through a validated Self-Injection Assessment Questionnaire (SIAQ), which evaluated patient experience at weeks 0, 4 and 12 on a scale of 0 (worst) to 10 (best) across six domains (feelings about injections, self-image, self-confidence, pain and skin reactions during or after the injection, ease of use of the self-injection device and satisfaction with self-injection). The mean score for "Satisfaction with Self Injection" was 9.18 (with 10 indicating "Very Satisfied") and the mean score for "Ease of Use" was 9.24 (with 10 indicating "Very Easy").

The efficacy and safety of Tremfya administered with One-Press in patients with moderate-to-severe plaque psoriasis was also evaluated in the double-blind, placebo-controlled ORION study. In the study, a greater proportion of patients in the Tremfya group achieved an IGA score of 0 or 1 or a PASI 90 response at week 16 (81 percent and 76 percent, respectively) than in the placebo group (0 percent for both endpoints). The proportion of patients who achieved an IGA score of 0 at week 16 was higher in the Tremfya group compared to the placebo group (56 percent vs. 0 percent). The proportion of patients who achieved a PASI 100 response at week 16 was higher in the Tremfya group compared to the placebo group (50 percent vs. 0 percent). The majority of injection-site reaction symptoms with One-Press were mild and transient in nature.

Find out more about Psoriasis in the Psoriasis Knowledge Centre